Search Result

Results for "

Pro-inflammatory cytokine inducer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Amyloid-β (1) Apoptosis (8) Autophagy (2) Calcium Channel (1) CaSR (1) CGRP Receptor (1) COX (2) EBI2/GPR183 (1) Endogenous Metabolite (1) Epigenetic Reader Domain (1) ERK (1) FOXO (1) Histone Acetyltransferase (1) HSP (2) Interleukin Related (6) JAK (1) Keap1-Nrf2 (2) Microtubule/Tubulin (1) MMP (1) NF-κB (10) NO Synthase (1) p38 MAPK (3) Parasite (2) Phosphatase (2) Phosphodiesterase (PDE) (1) Phospholipase (1) PI3K (1) Potassium Channel (2) PPAR (2) Prostaglandin Receptor (1) PTEN (2) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (3) Salt-inducible Kinase (SIK) (1) Sirtuin (1) STAT (1) STING (2) TNF Receptor (10) Toll-like Receptor (TLR) (2) TRP Channel (1) Wnt (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (3) Infection (4) Inflammation/Immunology (40) Metabolic Disease (4) Neurological Disease (4)

By Targets:

Akt (2)

Amyloid-β (1)

Apoptosis (8)

Autophagy (2)

Calcium Channel (1)

CaSR (1)

CGRP Receptor (1)

COX (2)

EBI2/GPR183 (1)

Endogenous Metabolite (1)

Epigenetic Reader Domain (1)

ERK (1)

FOXO (1)

Histone Acetyltransferase (1)

HSP (2)

Interleukin Related (6)

JAK (1)

Keap1-Nrf2 (2)

Microtubule/Tubulin (1)

MMP (1)

NF-κB (10)

NO Synthase (1)

p38 MAPK (3)

Parasite (2)

Phosphatase (2)

Phosphodiesterase (PDE) (1)

Phospholipase (1)

PI3K (1)

Potassium Channel (2)

PPAR (2)

Prostaglandin Receptor (1)

PTEN (2)

Radionuclide-Drug Conjugates (RDCs) (1)

Reactive Oxygen Species (3)

Salt-inducible Kinase (SIK) (1)

Sirtuin (1)

STAT (1)

STING (2)

TNF Receptor (10)

Toll-like Receptor (TLR) (2)

TRP Channel (1)

Wnt (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (3)

Infection (4)

Inflammation/Immunology (40)

Metabolic Disease (4)

Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128799

CL097	Toll-like Receptor (TLR) Reactive Oxygen Species	Inflammation/Immunology
CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages . CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production .

HY-128799A

CL097 hydrochloride	Toll-like Receptor (TLR) Reactive Oxygen Species	Inflammation/Immunology
CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages . CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production .

HY-149143

JNJ-28583113 1 Publications Verification	TRP Channel	Inflammation/Immunology
JNJ-28583113 is an TRPM2 antagonist with brain permeability. JNJ-28583113 inhibits TRPM2 blocked phosphorylation of GSK3α and β subunits. JNJ-28583113 protects cells from oxidative stress induced cell death. JNJ-28583113 also suppresses cytokine release in response to pro-inflammatory stimuli in microglia .

HY-P10350

PapRIV	NF-κB	Neurological Disease Inflammation/Immunology
PapRIV is an agonist of BV-2 microglial cells, capable of activating microglial cells through an NF-κB-dependent pathway. PapRIV induces the expression of pro-inflammatory cytokines such as IL-6 and TNFα and increases the production of reactive oxygen species (ROS). PapRIV can cross the blood-brain barrier .

HY-159614

PG-PS	TNF Receptor Interleukin Related	Inflammation/Immunology
PG-PS is a complex composed of streptococcal cell wall peptidoglycans and polysaccharides with pro-inflammatory and arthritis-inducing activity. PG-PS can be used to establish arthritis models. PG-PS can cause inflammation and joint damage, increase the expression of pro-inflammatory cytokines (TNF-α and IL-1β), and disrupt cellular redox balance .

HY-103438A

BIBU1361 dihydrochloride	Apoptosis Autophagy Akt	Cancer
BIBU1361 dihydrochloride induces apoptosis and inhibits autophagy. BIBU1361 inhibits pro-survival pathways Akt/mTOR and gp130/JAK/STAT3, and decreased levels of pro-inflammatory cytokine IL-6 .

HY-103438

BIBU1361	Apoptosis Akt Autophagy	Cancer
BIBU1361 induces apoptosis and inhibits autophagy. BIBU1361 inhibits pro-survival pathways Akt/mTOR and gp130/JAK/STAT3, and decreased levels of pro-inflammatory cytokine IL-6 .

HY-157211

Anti-inflammatory agent 66	NF-κB p38 MAPK	Inflammation/Immunology
Anti-inflammatory agent 66 (compound 8) is a pterostilbene derivative with anti-inflammatory activity. Anti-inflammatory agent 66 inhibits pro-inflammatory cytokines by blocking the LPS-induced NF-κB/MAPK signaling pathway and effectively alleviates DSS-induced acute colitis in mice .

HY-N12837

8-Epiloganin	Others	Inflammation/Immunology
8-Epiloganin can be isolated from Castilleja rubra and has anti-inflammatory properties. 8-Epiloganin inhibits LPS-induced release of pro-inflammatory cytokines, namely tumor necrosis factor-α and interleukin-1β .

HY-168034

diABZI-4	STING	Infection Inflammation/Immunology
diABZI-4 is an oral active STING agonist with broad-spectrum antiviral activity. diABZI-4 induces the production of pro-inflammatory cytokines and lymphocyte activation by activating STING, thereby inhibiting the replication of influenza A virus (IAV), SARS-CoV-2, and human rhinovirus (HRV), with an EC₅₀ range of 11.8-199 nM .

HY-149365

SIKs-IN-1	Salt-inducible Kinase (SIK)	Inflammation/Immunology
SIKs-IN-1 (compound 8h), a pyrimidine-5-carboxamide derivative, is a *Salt-inducible* kinases (SIKs*) inhibitor. SIKs regulates the transformation of M1/M2 macrophages, involving in inflammation process. SIKs-IN-1 inhibits SIK activity, up-regulates anti-inflammatory* cytokine IL-10, but down-regulates pro-inflammatory cytokine IL-12. SIKs-IN-1 shows excellent anti-inflammatory effects in a DSS-induced colitis model .

HY-N7012

7,3',4'-Tri-O-methylluteolin 5-Hydroxy-3',4',7-trimethoxyflavone	TNF Receptor Interleukin Related COX	Inflammation/Immunology
7,3',4'-Tri-O-methylluteolin (5-Hydroxy-3',4',7-trimethoxyflavone), a flavonoid compound, possesses potent anti-inflammatory effects in LPS-induced macrophage cell line mediated by inhibition of release of inflammatory mediators, NO, PGE2, and pro-inflammatory cytokines. 7,3',4'-Tri-O-methylluteolin significantly induces reduction in the mRNA expressions of inducible nitric oxide synthase and cyclooxygenase-2 .

HY-149426

SIRT5 inhibitor 7	Sirtuin	Inflammation/Immunology
SIRT5 inhibitor 7 (compound 58) is a substrate-competitive and selective SIRT5 inhibitor with anti-inflammatory activity. SIRT5 inhibitor 7 has renal protective effects and regulates protein succinylation and the release of pro-inflammatory cytokines. SIRT5 inhibitor 7 has in vivo activity in AKI mouse models of lipopolysaccharide (LPS) and cecal ligation/perforation (CLP)-induced sepsis-related acute kidney injury .

HY-P9983

Lintuzumab HuM-195	Others Radionuclide-Drug Conjugates (RDCs)	Inflammation/Immunology
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR? and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .

HY-148552

Anti-inflammatory agent 35	p38 MAPK ERK NF-κB Interleukin Related TNF Receptor	Inflammation/Immunology
Anti-inflammatory agent 35 (compound 5a27) is an orally active curcumin analogue with anti-inflammatory activity. Anti-inflammatory agent 35 blocks mitogen-activated protein kinase (MAPK) signaling and p65 nuclear translocation of NF-kB. Anti-inflammatory agent 35 also inhibits yellow neutrophil infiltration and pro-inflammatory cytokine production. Anti-inflammatory agent 35 significantly attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI) in vivo .

HY-162011

GPR183 antagonist-2	EBI2/GPR183	Inflammation/Immunology
GPR183 antagonist-2 (compound 32) is a selective GPR183 antagonist with good water solubility and excellent pharmacokinetic properties. GPR183 antagonist-2 significantly reduces paw and joint swelling and gene expression of pro-inflammatory cytokines (MCP-1, MMPs, and VEGF) in a collagen-induced arthritis (CIA) mouse model in a dose-dependent manner. GPR183 antagonist-2 can be used in the study of autoimmune diseases .

HY-149246

Aβ-IN-6	Amyloid-β Keap1-Nrf2	Neurological Disease Inflammation/Immunology
Aβ-IN-6 reduces pro-inflammatory cytokine release from microglia cells. Aβ-IN-6 significantly induces Nrf2 nuclear translocation and hamperes Aβ oligomers formation. Aβ-IN-6 exerts a consistent neuroprotective effect by modulating the redox-sensitive signalling pathways in vivo oxidative stress model. Aβ-IN-6 is an orally active and has antiinflammatory, Antioxidant and Anti-oligomeric activity. Aβ-IN-6 has the potential for Alzheimer's disease (AD) research .

HY-117694

MK-8825	CGRP Receptor	Neurological Disease Inflammation/Immunology
MK-8825 is an orally active, potent and selective CGRP receptor antagonist, which shows concentration-dependent inhibition of Capsaicin (HY-10448)-evoked dermal blood flow with an EC₅₀ value of about 7.4 μM. MK-8825 inhibits CGRP-induced spontaneous nociceptive facial grooming behaviors, neuronal activation in the trigeminal nucleus, and systemic release of pro-inflammatory cytokines in a mouse model of acute orofacial masseteric muscle pain. MK-8825 is promising for research of acute migraine .

HY-123461

Sul-121 hydrochloride	Others	Inflammation/Immunology
Sul-121 hydrochloride is a novel compound with anti-oxidative capacity that effectively inhibits airway inflammation and hyperresponsiveness (AHR) in experimental models of chronic obstructive pulmonary disease (COPD). Sul-121 hydrochloride prevents lipopolysaccharide-induced airway neutrophilia and AHR in a dose-dependent manner. Sul-121 hydrochloride also demonstrates the ability to reduce oxidative stress markers in human airway smooth muscle cells. Sul-121 hydrochloride inhibits nuclear translocation of the NF-κB subunit, p65, thereby diminishing pro-inflammatory cytokine release.

HY-N0515

Ophiopogonin D	PPAR NF-κB Calcium Channel	Cardiovascular Disease Inflammation/Immunology
Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C₂₉ steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca ²⁺ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .

HY-159580

STAT3-IN-31	STAT	Cancer
STAT3-IN-31 (compound K2071) is a STATtic-derived STAT3 and mitotic inhibitor. STAT3-IN-31 blocks mitotic progression and affects the formation of mitotic spindles. STAT3-IN-31 also affects glioblastoma cell migration and inhibits cell proliferation in tumor spheroids. STAT3-IN-31 is also able to induce glioblastoma senescence, inhibit the growth of Temozolomide (HY-17364)-resistant cells and the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein MCP-1 .

HY-N0807

Swertiamarin	MMP NF-κB JAK Keap1-Nrf2	Metabolic Disease Inflammation/Immunology Cancer
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating JAK2/STAT3 transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis .

HY-136065

bpV(phen) 2 Publications Verification	PTEN Phosphatase Parasite Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
bpV(phen), a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC₅₀s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity .

HY-122818

bpV(phen) trihydrate 2 Publications Verification	PTEN Phosphatase Parasite Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
bpV(phen) trihydrate, a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC₅₀s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) trihydrate inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) trihydrate strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) trihydrate can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity .

HY-N1934

Dihydroberberine	Potassium Channel HSP	Cardiovascular Disease Inflammation/Immunology Cancer
Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-118312

CAY10657	NF-κB	Inflammation/Immunology
CAY10657 is an inhibitor for NF-κB pathway. CAY10657 downregulates expressions of proinflammatory cytokine (IL-6) and chemokine (MCP-1), and thus exhibits anti-inflammatory efficacy against meningitis induced by Streptococcus suis .

HY-159131

PNSC928	Histone Acetyltransferase Epigenetic Reader Domain	Inflammation/Immunology
PNSC928 is an inhibitor for the CtBP2-p300 interaction with an IC₅₀ of 23.60 µM, and reverses the Lipopolysaccharides (HY-D1056)-induced expressions of proinflammatory cytokines in RAW264.7. PNSC928 ameliorates the acute respiratory distress syndrome (ARDS)in mice .

HY-P1860

TNF-α (31-45), human 5 Publications Verification	TNF Receptor NF-κB Apoptosis	Inflammation/Immunology Cancer
TNF-α (31-45), human is a potent NF-kB pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .

HY-N1934R

Dihydroberberine (Standard)	Potassium Channel HSP	Cardiovascular Disease Inflammation/Immunology Cancer
Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-P1860A

TNF-α (31-45), human TFA	TNF Receptor NF-κB Apoptosis	Inflammation/Immunology
TNF-α (31-45), human TFA is a potent NF-kB pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .

HY-111164

CBS-3595	p38 MAPK Phosphodiesterase (PDE)	Inflammation/Immunology
CBS-3595 is a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 with anti-inflammatory and anti-allodynic activities. CBS-3595 reduces the production of the proinflammatory cytokine IL-6 and increases the levels of the anti-inflammatory cytokine IL-10 in rats. CBS-3595 reduces paw oedema formation in the Complete Freund’s adjuvant (CFA) (HY-153808)-induced arthritis rat model. CBS-3595 is promising for research of autoimmune diseases .

HY-149816

Anti-inflammatory agent 41	Interleukin Related TNF Receptor NF-κB	Inflammation/Immunology
Anti-inflammatory agent 41 (13a) significantly inhibit lipopolysaccharide (LPS)-induced expression of the proinflammatory cytokines IL-6 and TNF-α on J774A.1, THP-1 and LX-2 cells, and inhibits the activation of the NF-κB pathway .

HY-N12042

Taxamairin B	TNF Receptor PI3K Reactive Oxygen Species Interleukin Related	Inflammation/Immunology
Taxamairin B is a potent anti-inflammatory agent. Taxamairin B decreases proinflammatory cytokines (TNF-α, IL-1β and IL-6) expression and the production of NO and ROS in LPS-induced RAW264.7 cells. Taxamairin B exhibits significant protective effects in LPS-induced acute lung injury in mice .

HY-N8936

Narchinol B	Others	Inflammation/Immunology
Narchinol B (Compound 4) is a sesquiter penoid compound. Narchinol B has anti-inflammatory effects. Narchinol B works by inhibiting proinflammatory mediators, including prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) proteins, as well as proinflammatory cytokines, such as interleukin-1b, IL-6, and tumor necrosis factor-α (TNF-α). Narchinol B significantly inhibits LPS-induced overproduction of NO in BV2 cells (IC₅₀=2.43 μM) .

HY-N3021

D-chiro-Inositol	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin	Metabolic Disease
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-12557

γ-Glutamylvaline	CaSR Wnt TNF Receptor	Inflammation/Immunology
γ-Glutamylvaline is an activator of CaSR with anti-inflammatory activity. γ-Glutamylvaline inhibits *TNF-α*-induced proinflammatory cytokine production and increases Wnt5a expression. γ-Glutamylvaline activates calcium-sensing receptor pathways in adipocytes of 3T3-L1 mice and prevents low-grade chronic inflammation .

HY-N13232

Grape Skin Extract	Others	Neurological Disease
Grape Skin Extract is a grape skin extract, and its ingredients include: Polyphenols. Grape Skin Extract has neuroprotective effects and can improve Aβ-induced cytotoxicity to SH-SY5Y cells. Grape Skin Extract can increase the proliferation and memory of neurogenic areas, but reduce the oxidative stress associated with proinflammatory cytokines during aging, thereby protecting neurons. .

HY-138990

GK563	Phospholipase Apoptosis	Inflammation/Immunology
GK563 is a selective Ca ²⁺-independent phospholipase A₂ (GVIA iPLA₂) inhibitor with an IC₅₀ value of 1 nM. GK563 is 22000 times more active against GVIA iPLA₂ than GIVA cPLA₂. GK563 reduces β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes .

HY-152955

STING agonist-22	STING	Infection Inflammation/Immunology
STING agonist-22 (CF501) is a potent non-nucleotide STING agonist. STING agonist-22 is a adjuvant by activating STING to induce the type I interferon (IFN-I) response and proinflammatory cytokine production. STING agonist-22 can be used as an adjuvant to boost the original protein vaccine, producing potent, broad, and long-term immune protection. STING agonist-22 can be used for SARS-CoV-2 variants and sarbecovirus diseases research .

HY-162963

PPARδ agonist 11	PPAR	Inflammation/Immunology
PPARδ agonist 11 (Compound 11) is a selective agonist for PPARδ with an EC₅₀ of 20 nM. PPARδ agonist 11 reduces the levels of nitrite oxide (NO), proinflammatory cytokines TNFα and IL-6 in LPS (HY-D1056)-stimulated RAW264.7 cell, and exhibits anti-inflammatory efficacy via NF-κB pathway. PPARδ agonist 11 exhibits good stability in human liver microsomes and plasma. PPARδ agonist 11 ameliorates Carrageenan (HY-125474)-induced foot edema, and exhibits good pharmacokinetic characteristics with an bioavailability of ca. 100% .

HY-B0367

Lornoxicam Chlortenoxicam; Ro 13-9297	Apoptosis COX NO Synthase Interleukin Related Prostaglandin Receptor TNF Receptor	Inflammation/Immunology Cancer
Lornoxicam (Chlortenoxicam) is an orally active oxycontin nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, antipyretic and anticancer activities. Lornoxicam exhibits good inhibitory effects on both COX-1 and COX-2 (COX-1: IC₅₀=0.005 μM; COX-2:IC₅₀=0.008 μM) and inhibits the production of NO by iNOS (IC₅₀=65 μM) and the proinflammatory cytokine IL-6 (IC₅₀=54 μM). Lornoxicam also inhibits tumor cell proliferation and migration and induces tumor cell apoptosis. Lornoxicam can be used in the study of inflammatory pain, colorectal cancer and breast cancer .

HY-N9541

Chaetoglobosin Vb	Others	Inflammation/Immunology
Chaetoglobosin Vb is a novel cytotoxic alkaloid with anti-inflammatory and antioxidant activities. Chaetoglobosin Vb can inhibit oxidative stress induced by LPS stimulation, reduce the production of reactive oxygen species and increase the expression of the antioxidant enzyme superoxide dismutase (SOD). Chaetoglobosin Vb significantly reduced the gene and protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) induced by LPS, and alleviated the production of proinflammatory cytokines such as TNF-α, IL-6 and IL-1β. Chaetoglobosin Vb exerts its biological activity through the TLR4-mediated MyD88-dependent signaling pathway and the TRIF-dependent signaling pathway, which is specifically manifested by inhibiting the phosphorylation of p38, ERK, and JNK MAPK and the translocation of NF-κB p65 subunit to the nucleus. Chaetoglobosin Vb showed no cytotoxic effect in the concentration range of 25-100 μM and promoted SOD enzyme activity and phosphorylation of p38, ERK1/2 and JNK in a dose-dependent manner .

Cat. No.	Product Name

HY-L156

Autoimmune Disease Compound Library	531 compounds
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A). MCE designs a unique collection of 531 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Autoimmune Disease Compound Library

531 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 531 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Cat. No.	Product Name	Target	Research Area

HY-P10136

IA9 human TREM-2 182-190	Peptides	Inflammation/Immunology
IA9 (human TREM-2 182-190) is a TREM-2 inhibitor , and can diminish release of proinflammatory cytokines and dramatically suppressed joint inflammation and damage in collagen-Induced Arthritis (CIA) mice model .

HY-P10136A

IA9 TFA human TREM-2 182-190 TFA	Peptides	Inflammation/Immunology
IA9 TFA (human TREM-2 182-190 TFA) is a TREM-2 inhibitor , and can diminish release of proinflammatory cytokines and dramatically suppressed joint inflammation and damage in collagen-Induced Arthritis (CIA) mice model .